---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-124592"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:44:28.370990+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Liquidia collaborates with Sandoz and Mainbridge to develop new pump for treprostinil; promotion deal extended to 2032

## Summary
- Development agreement with Mainbridge to create new subcutaneous pump for treprostinil injection, targeting 510(k) submission in 2023.
- Sandoz and Liquidia will equally split development costs; Mainbridge to perform all development, validation, and testing.
- Promotion agreement for Treprostinil Injection extended by five years, now through December 31, 2032.
- New pump aims to reduce single-source dependence on existing CADD-MS 3 system for PAH patients.

## SEC filing metadata
- accession: 0001104659-22-124592
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465922124592/0001104659-22-124592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465922124592/tm2231990d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-124592
- JSON: https://secwatch.observer/filing/0001104659-22-124592.json
- Plain text: https://secwatch.observer/filing/0001104659-22-124592.txt

## Key facts
- Material Agreements
  Liquidia Corp entered into Pump Development Agreement with Mainbridge Health Partners, LLC and Sandoz Inc. (effective 2022-12-01).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Mainbridge Health Partners, LLC and Sandoz Inc.
  - Effective: 2022-12-01
  source text: On December 1, 2022, Liquidia PAH, LLC, a Delaware limited liability company (“Liquidia PAH”), a wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Device Development and Supply Agreement (the “Pump Development Agreement”) with Mainbridge Health Partners, LLC (“Mainbridge”) and Sandoz Inc. (“Sandoz”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819576/000110465922124592/0001104659-22-124592-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.